Adalimumab Injection [Humira](AbbVie)은 Mucopolysaccharidosis I 표적 항체로, Mucopolysaccharidosis I; Mucopolysaccharidosis II 영역에서 개발·상용화 중입니다. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: unique property can be exploited to design drug delivery systems that allow an extended residence time and thus action of the.
Mucopolysaccharidosis I
Mucopolysaccharidosis I; Mucopolysaccharidosis II
Recruiting
unique property can be exploited to design drug delivery systems that allow an extended residence time and thus action of the
apoptosis of the TNF-α/TNFR1/NF-κB/c-FLIP axis to control lung colonization of triple negative breast cancer
biomarker for adalimumab treatment of TNBC patients
Downregulation of SCEL expression significantly impaired the 3D colony-forming ability but not the migration and invasion ability of t
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Adalimumab Injection [Humira](AbbVie)은 Mucopolysaccharidosis I 표적 항체로, Mucopolysaccharidosis I; Mucopolysaccharidosis II 영역에서 개발·상용화 중입니다. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: unique property can be exploited to design drug delivery systems that allow an extended residence time and thus action of the.
Mucopolysaccharidosis I
Mucopolysaccharidosis I; Mucopolysaccharidosis II
Recruiting
unique property can be exploited to design drug delivery systems that allow an extended residence time and thus action of the
apoptosis of the TNF-α/TNFR1/NF-κB/c-FLIP axis to control lung colonization of triple negative breast cancer
biomarker for adalimumab treatment of TNBC patients
Downregulation of SCEL expression significantly impaired the 3D colony-forming ability but not the migration and invasion ability of t
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.